Chief Financial Officer · Arcutis Biotherapeutics, Inc. (ARQT)

Scott Burrows

A named executive officer of Arcutis Biotherapeutics in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,246,136

Salary $386,667Stock awards $235,011

FY2021: $2,080,377

5th of 5 named executive officers at Arcutis Biotherapeutics by FY2022 total.

5 named officers on file for Arcutis Biotherapeutics, FY2022

Scott Burrows’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • ARQT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Arcutis Biotherapeutics’s whole pay program stands against its peers

  • Arcutis Biotherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ARQT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 18, 2023 (DEF 14A).

Free

Get Scott Burrows’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Scott Burrows compensation by year

Arcutis Biotherapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Arcutis Biotherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$330,750$386,667
Bonus$0$0
Stock awards$90,832$235,011
Option awards$1,481,820$434,391
Non-equity incentive$165,375$177,867
Pension and deferred compensation$0$0
All other$11,600$12,200
Total$2,080,377$1,246,136

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 18, 2023, accession 0001787306-23-000033, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Arcutis Biotherapeutics, Inc. filed document, accession 0001787306-23-000033. Every figure is read from that document and cited to the page and table it appears in. Filed April 18, 2023.

$2.1M
$1.2M
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU13,300$196,840—
RSU2,100$31,080—
RSU2,000$29,600—
Option2,291—$6.52
Option7,289—$1.68
Option292—$27.61
Option13,417—$29.74
Option4,781—$32.44
Option41,778—$20.59
Option28,681—$17.67

Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Arcutis Biotherapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Masaru MatsudaGeneral Counsel$5,142,764
Todd Franklin WatanabePresident and Chief Executive Officer$4,581,555
Patrick BurnettM.D., Ph.D. Chief Medical Officer$1,584,078
Kenneth LockChief Commercial Officer$1,270,018
Scott Burrows · this pageChief Financial Officer$1,246,136

The full Arcutis Biotherapeutics compensation record

free company brief

This page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Arcutis Biotherapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Scott Burrows's compensation dossier · One-time report. No refunds.